As patient-centered drug design and personalized medicine gain prominence, pharmaceutical companies must navigate more intricate clinical and regulatory landscapes, necessitating greater operational efficiency. In the pharma industry, outsourcing to specialized partners has become common practice, allowing companies to accelerate innovation, streamline workflows and scale cost-effectively, ensuring faster time-to-market while maintaining high-quality drug development and manufacturing standards.
Modern outsourcing relationships have become more strategic and technologically sophisticated, solidifying these partnerships as key enablers of the pharmaceutical landscape. As these contract development and manufacturing organizations (CDMOs) and contract research, development and manufacturing organizations (CRDMOs) work to stay competitive, they are looking to build capability and expertise in continuous manufacturing, automation, AI-driven analytics and digital process controls.
Integrating these emerging technologies in outsourcing is not only driving efficiencies in formulation, production and packaging, but also strengthening supply chain resiliency by taking deliberate steps resulting in a scalable, technologically advanced pharmaceutical manufacturing ecosystem. It has also facilitated significant growth in the global pharma manufacturing outsourcing market valued at $161.76 billion in 2023 and projected to reach $300.34 billion by 2032, with a compound annual growth rate of 7.15%.
Leveraging Technology and Innovation
For new drug products, technology and innovation are impacting drug development as drug sponsors look to reduce costs and shrink time to market. Technologies are also influencing the balance between outsourcing, supply chain resiliency and reshoring. Advanced manufacturing technologies, such as continuous manufacturing, automation and AI-driven process optimization are capable of reducing production costs and increasing efficiency, making manufacturing more viable in traditionally high-cost regions. This shift supports reshoring efforts while maintaining global competitiveness.
In this environment, drug sponsors are looking to partner with CDMOs equipped with everything from dosage form design capabilities to strategic commercial operation support. Figure 1 highlights the breadth of innovations shaping the industry and the critical role CDMOs play in handling these advancements.
To better understand how CDMOs are leveraging innovation to support drug sponsors’ strategic and business goals, we take a closer look at key areas where CDMO-driven advancements are making an impact.
Patient-Centric Dosage Forms
Personalized health care is driving major advancements in pharma manufacturing, particularly in capsule technology, so CDMOs with specialized expertise in hard and soft capsules play a vital role in helping drug sponsors optimize drug therapies, leveraging innovative delivery systems tailored to patient needs.
Once a simple dosage form, hard gelatin capsules have evolved into sophisticated drug delivery systems, offering enhanced bioavailability, controlled release and improved patient compliance. As pharma companies focus on more targeted treatments, capsule innovations are a key driver of drug formulation and therapeutic success. Originally developed for nutraceuticals containing unstable ingredients, advanced capsule systems now enable the co-delivery of multiple active ingredients that would otherwise degrade when mixed, making them an ideal solution for combination therapies. This innovation not only enhances treatment efficacy but also expands the possibilities for personalized medicine and multi-drug regimens.
Growth in the soft gelatin capsule (softgel) market is driven by consumer demand for easy-to-swallow supplements, improved bioavailability and enhanced ingredient stability. The smooth texture and ability to mask unpleasant tastes and odors make softgels a preferred alternative to traditional tablets or hard capsules, particularly among elderly and pediatric populations. Additionally, the growing interest in plant-based and vegetarian softgels is expanding the market, catering to diverse dietary preferences. Compared to tablets and hard capsules, softgels offer faster dissolution and absorption, superior stability for liquid ingredients, and greater patient compliance due to their easier-to-swallow format. Their sealed, protective environment extends the shelf life of sensitive ingredients, making them ideal for nutraceuticals, pharmaceuticals and specialty formulations.
The demand for enteric softgel capsules, which dissolve in the small intestine rather than the stomach, is also rising, as they protect acid-sensitive ingredients and enhance patient adherence. As technological advancements continue to refine softgel manufacturing and formulation, the market is poised for sustained global growth, solidifying softgels as a versatile and patient-friendly dosage form.
New Technologies in Quality and Manufacturing
In the rapidly evolving CDMO landscape, the integration of digital technologies is proving to be a significant differentiator. By leveraging machine learning algorithms and predictive analytics, AI can optimize process parameters in real time, ensuring optimal conditions for drug formulation and production. This not only enhances the quality and consistency of pharmaceutical products but also significantly reduces waste and downtime, leading to cost efficiency.
CDMOs are also leveraging digital twins and predictive modeling to accelerate drug development by integrating and managing real-time data from various sources. This data is essential for creating an accurate digital model that simulates the drug development process under development and predicts outcomes. Using virtual models, CDMOs can simulate manufacturing processes, identify potential issues, and optimize them without the need for physical trials, leading to faster and more efficient drug development. CDMOs leverage these models with drug sponsors when extensive optimization is not financially viable or when developing supply agreements where performance and yield have a profound impact on the CDMO’s profitability.
AI is having a significant impact is the analytical laboratory, where integrating AI technologies significantly enhances analytical validation. Advanced platforms provide an integrated framework for data management and data flow addressing the laboratory information management system (LIMS), electronic laboratory notebook (ELN), data infrastructure and cloud storage requirements with an efficient and agile AI framework. These systems have the ability to integrate predictive modeling as well as accelerating stability testing by simulating extended storage conditions in a fraction of the time, enabling rapid identification of degradation pathways.
Machine learning algorithms process high-resolution LC-MS and DLS data to pinpoint impurities and contaminants, ensuring production batches maintain consistent quality. AI technologies, including advanced imaging and robotic process automation, can detect even the slightest deviations from expected results, flagging potential issues before they affect product quality. This proactive approach ensures compliance with stringent regulatory standards and also safeguards patient safety.
For regulatory adherence, automated systems streamline the preparation of submission-ready documents, monitor real-time regulatory updates, and evaluate the compliance impact of process modifications, minimizing administrative overhead while improving accuracy.
AI and Data Integrity
One of the most significant advantages of AI in the CDMO industry is its ability to aid in complex decision-making. CDMOs must manage programs at every phase of the drug development while maintaining ironclad confidentiality between customers, yet all of these customers share the same CDMO quality and operational systems. AI is optimizing decision-making for CDMOs while maintaining customer confidentiality through several innovative approaches.
Data segmentation and access control ensure sensitive information from different customers remains separate, even when using shared quality and operations systems. Federated learning allows for training machine learning models across multiple datasets without sharing actual data, preserving proprietary information. Anonymization and encryption enable trend analysis and process optimization without revealing specific customer details. Role-based access controls ensure only authorized personnel can access sensitive data, minimizing the risk of breaches.
AI systems can analyze vast amounts of data, from development data to production metrics to identify patterns and predict outcomes. This capability allows CDMOs to make informed decisions about everything from resource allocation to process adjustments, to respond swiftly and effectively to any challenges that arise.
Artificial and Virtual Reality
Artificial reality (AR) and virtual reality (VR) are transforming drug development and manufacturing within CDMOs by providing immersive and interactive tools that enhance various aspects of the process. In training and education, where CDMOs support many drug sponsors, AR and VR create virtual environments where staff can practice complex procedures and operations to reduce the risk of errors and improve the skill levels of employees. Additionally, VR simulations of manufacturing processes allow CDMOs to identify potential bottlenecks and optimize workflows before implementing them in the real world, leading to more efficient and cost-effective production.
As supply chains remain global, AR and VR are also being applied to facilitate remote collaboration. These technologies enable virtual meetings and walkthroughs of manufacturing facilities, allowing CDMOs to work closely with clients and partners in real time, regardless of their physical location. AR also plays a crucial role in quality control and assurance by overlaying digital information onto physical equipment and processes, helping technicians quickly identify and address issues, ensuring compliance with regulatory standards. Furthermore, VR aids in product design and development by allowing scientists to visualize and manipulate molecular structures and drug formulations in a virtual space, providing a deeper understanding of their properties and interactions.
Several AR/VR tools are being used by CDMOs to achieve these benefits. The number of AR/VR solution providers is rapidly increasing, offering solutions such as full-body tracking and advanced glove technologies for tactile interactions in virtual reality. CDMOs can significantly enhance their training programs, optimize manufacturing processes and facilitate effective remote collaboration, ultimately improving the overall drug development and manufacturing process.
Data Quality and Management
The need to develop robust data quality and data management expertise and capability is a critical factor impacting today’s pharma CDMOs. Data quality becomes essential to manage and maintain as CDMOs move from early phase drug development to late stage and commercial support. In addition, all innovations from AI to VR are predicated on high quality data. CDMOs are investing in expertise and capability to effectively support the volume and quality of data drug sponsors. By prioritizing data quality and implementing effective data management systems, CDMOs are enhancing their operational capabilities while supporting a higher quality drug development exercise with their drug sponsor.
An Outsourcing Transformation
Driven by technological advancements and the strategic evolution of CDMOs and CRDMOs, the pharmaceutical outsourcing industry is undergoing a profound transformation. No longer mere contract service providers, these organizations are critical innovation partners, integrating AI, automation and digital process optimization to enhance efficiency, quality and scalability in drug development and manufacturing.
In parallel, capsule and softgel innovations are reshaping dosage form development, offering enhanced bioavailability, controlled release mechanisms and patient-friendly formulations. The industry is witnessing a rapid shift toward personalized medicine, with CDMOs developing advanced drug delivery systems that support combination therapies and tailored treatment approaches.
The shift is no longer on the horizon — it is happening now. CDMOs and CRDMOs are actively reshaping pharmaceutical manufacturing, leveraging technology to shorten development timelines, strengthen supply chain resiliency and improve patient outcomes. As outsourcing becomes more integrated, data-driven and technologically advanced, these partnerships are setting new standards for excellence in the pharmaceutical industry.
References
Pharmaceutical Contract Manufacturing Market Size to Worth USD 300.34 Billion by 2032. SNS Insider. Feb. 2025.
Next-generation technology for capsule-based oral solid dosage forms. NBR. Nov. 2023.
The Vital Role of AI in Enhancing CDMO Operations: A FutureReady Approach. Pharma Intro. April 2024.
Knorr, A. The Virtual Lab: How VR & AI Are Transforming the Pharmaceutical Industry. 3Spin Learning. Feb. 2024.
Haywood, J. Driving quality and efficiency: The role of chromatography data systems in pharma CDMOs. Sterling. Jan. 2025.